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Background: Intravenous salbutamol (albuterol) reduces lung water in patients with the acute respiratory
distress syndrome (ARDS). Experimental data show that it also reduces pulmonary neutrophil accumulation or
activation and inflammation in ARDS.
Aim: To investigate the effects of salbutamol on neutrophil function.
Methods: The in vitro effects of salbutamol on neutrophil function were determined. Blood and
bronchoalveolar lavage (BAL) fluid were collected from 35 patients with acute lung injury (ALI)/ARDS, 14
patients at risk from ARDS and 7 ventilated controls at baseline and after 4 days’ treatment with placebo or
salbutamol (ALI/ARDS group). Alveolar–capillary permeability was measured in vivo by thermodilution
(PiCCO). Neutrophil activation, adhesion molecule expression and inflammatory cytokines were measured.
Results: In vitro, physiological concentrations of salbutamol had no effect on neutrophil chemotaxis, viability
or apoptosis. Patients with ALI/ARDS showed increased neutrophil activation and adhesion molecule
expression compared with at risk-patients and ventilated controls. There were associations between alveolar–
capillary permeability and BAL myeloperoxidase (r = 0.4, p = 0.038) and BAL interleukin 8 (r = 0.38,
p = 0.033). In patients with ALI/ARDS, salbutamol increased numbers of circulating neutrophils but had no
effect on alveolar neutrophils.
Conclusion: At the onset of ALI/ARDS, there is increased neutrophil recruitment and activation. Physiological
concentrations of salbutamol did not alter neutrophil chemotaxis, viability or apoptosis in vitro. In vivo,
salbutamol increased circulating neutrophils, but had no effect on alveolar neutrophils or on neutrophil
activation. These data suggest that the beneficial effects of salbutamol in reducing lung water are unrelated to
modulation of neutrophil-dependent inflammatory pathways.
A
cute lung injury (ALI) and the acute respiratory distress
syndrome (ARDS) are major causes of respiratory failure
in the critically ill patient.1 Although controversy still
exists regarding the role of neutrophils in all causes of ALI,2 a
recent systematic review of laboratory and clinical studies
concluded that neutrophils played a central part in most cases.3
Pathophysiologically, ARDS is characterised by intense inflam-
mation in the alveolar space, with a predominance of
neutrophils. Analysis of bronchoalveolar lavage (BAL) fluid
from patients with ARDS has shown increased numbers of
activated neutrophils in the early stages of ARDS.4 5 The
number of neutrophils in BAL fluid relates to the severity of
lung injury,6 and the persistence of neutrophils is associated
with increased mortality.5 A study examining BAL fluid from
patients with ARDS showed a positive correlation between
neutrophil myeloperoxidase (MPO) and oxidatively modified
amino acids, suggesting an association between pulmonary
neutrophil activation and oxidative protein damage.7 Animal
studies have shown that neutrophil-mediated lung injury
reduces alveolar fluid clearance, preventing the resolution of
non-cardiogenic pulmonary oedema.8 Neutrophil elastase inhi-
bitors in animal models limit the degree of lung injury caused
by ischaemia reperfusion9 and lipopolysaccharide (LPS),10
although a recent multicentre clinical trial of the elastase
inhibitor Sivelestat failed to improve outcome in a hetero-
geneous group of patients with ARDS.11
b2-agonists have several inhibitory effects on neutrophil
function.12 In animal models of acute lung injury, b2-agonists
reduce pulmonary neutrophil sequestration.13 14 In vitro b2-
agonists reduce the production of oxygen free radicals from
neutrophils and other inflammatory cells15 16 and reduce
inflammatory cytokine production.17 In humans, inhaled
salmeterol (long-acting b2-agonist) inhibited LPS-induced
neutrophil influx, degranulation and tumour necrosis factor
(TNF)a release.18 These experimental findings suggest that
treatment with a b2-agonist could have a favourable effect in
ARDS by reducing neutrophilic inflammation.
We recently conducted a randomised controlled trial in
humans with ARDS (b-agonist lung injury trial (BALTI-1)
study), and showed that intravenous salbutamol (albuterol)
markedly reduced extravascular lung water probably through
up regulation of alveolar fluid clearance.19 However, the
reduction in lung water was not seen until 48 h after the
initiation of treatment, suggesting some effects in addition to
alveolar fluid clearance. The objective of this study was to
investigate whether salbutamol modulates neutrophil function
and neutrophilic inflammation at physiologically relevant doses
in patients with ALI. The second objective was to investigate the
relationship between neutrophilic inflammation and alveolar
capillary permeability in patients with ARDS.
MATERIALS AND METHODS
In vitro studies
Under-agarose chemotaxis, cell viabili ty and
apoptosis
Neutrophils from non-smoking, healthy controls were purified
from peripheral blood by discontinuous Percoll density gradi-
ents.20 The effect of salbutamol on the chemotactic activity of
purified neutrophils was measured using the under-agarose
Abbreviations: ALI, acute lung injury; ARDS, acute respiratory distress
syndrome; BAL, bronchoalveolar lavage; FMLP, N-formyl-L-leucin-
methionyl-L-phenylalanine; LPS, lipopolysaccharide; TNF, tumour necrosis
factor
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method.21 The freshly harvested neutrophils were resuspended
at 56107 cells/ml in RPMI (Sigma, UK) 1640 culture medium or
1025–10210 M salbutamol in RPMI (with or without propra-
nolol 1024 M) before seeding in 10-ml aliquots in the central
wells of a freshly prepared agarose plate. In all, 10 ml of RPMI
was placed in each of the inner wells and 10 ml of chemoat-
tractant (1027 N-formyl-L-leucin-methionyl-L-phenylalanine
(FMLP, Sigma, UK) in RPMI) in each of the outer wells.
Negative controls contained RPMI in the inner and outer wells.
The plates were incubated at 37 C˚ (5% CO2) for 2 h and then
flooded with methanol for overnight fixation of the cells. The
gel was carefully removed and the plates washed under slow
running tap water. The plates were then stained with Gram
stain and left to dry. For each well, the chemotactic and
chemokinetic responses were read using an eyepiece graticule.
The overall response to the chemoattractant (chemotactic
differential) was calculated by subtracting the chemokinetic
response from the chemotactic response.
Purified neutrophils, suspended in RPMI at a concentration
of 16106 ml, were incubated with 1025 and 1027 M salbutamol
or RPMI control for 2 h at 37 C˚ in humidified 5% CO2. Cell
proliferation was assessed by adding 20 ml of CellTiter 96
AQueous one solution (Promega, Southampton, UK) to 100 ml
of cell suspension in a 96-well culture plate (Nunc). The
reaction was allowed to proceed for 2 h at 37 C˚ in 5% CO2. The
cell titre solution contains a tetrazolium compound that is
metabolised by healthy cells to a formazan product, the
absorbance of which was read at 495 nm on an MRX-II 96-
well plate reader (Dynex Technologies, Sussex, UK).
Purified neutrophils, suspended in RPMI with 10% heat-
inactivated fetal calf serum (Life Technologies) and 100 units/
ml penicillin and 100 mg/ml streptomycin (Sigma, Poole, UK)
at a concentration of 16106 ml, were incubated with 1025 and
1027 M salbutamol or RPMI control for 18 h at 37 C˚ in
humidified 5% CO2. Preliminary experiments showed that
18 h was the optimal time point for assessing apoptosis. The
number of normal and apoptotic neutrophils were determined
by morphological patterns. After centrifugation, samples were
stained using a commercial May–Grunwald Giemsa stain (Diff-
Quick, Baxter Healthcare Product, Deerfield, Illinois, USA). The
percentage apoptotic cells compared with total number of cells
were calculated. The morphological results were confirmed
using flow cytometry and the annexin V/propidium iodine
apoptosis kit (Dako, Carpinteria, California, USA). The percen-
tages of live (annexin and propidium iodine negative) and early
apoptotic (annexin positive, prodipium iodine negative) or late
apoptotic/dead (annexin positive, prodipium iodine positive)
cells were calculated.
Clinical study
Mechanically ventilated adult patients enrolled in the BALTI-1
study were eligible for inclusion.19 This study recruited patients
within 48 h of the onset of ALI and ARDS and randomised
them to 7 days of treatment with intravenous salbutamol
(15 mg/kg/h). ALI was defined according to the American
European Consensus Conference definition22 as the acute onset
of respiratory failure with a arterial oxygen tension:fractional
oxygen tension (PaO2:FiO2) ratio of ,300 mm Hg and bilateral
infiltrates on the chest radiograph in the absence of clinical
evidence of left atrial hypertension. ARDS was considered
present when the PaO2:FiO2 ratio was ,200 mm Hg. The
exclusion criteria were as follows: age ,18 years; participation
in other intervention trials; severe obstructive airway disease
requiring nebulised or intravenous b2-agonist; treatment with
b-blockers within 48 h; neutrophil count ,0.36109 l; brain
stem death; treatment withdrawal within 24 h; immunosup-
pression (steroids .20 mg/day, chemotherapy or other immu-
nosuppressive agents within 2 weeks); lobectomy/
pneumonectomy; burns .40% body surface area; assent
declined from the next of kin.
Patients with identifiable risk factors for ALI/ARDS, but who,
at the time of recruitment had not met the criteria for
Figure 1 (A) Salbutamol 1025 M and
1024 M significantly reduced neutrophil
chemotaxis towards the chemotractant
stimulus FMLP. (B) No effect was seen on
neutrophil chemokineses. (C) The effect of
salbutamol on neutrophil chemotaxis was
blocked by incubation with 1024 M
propranolol. (D) Salbutamol (1026 and
1024 M) had no effect on the rate of
apoptosis at 18 h (apoptosis determined by
morphology (grey bars) and flow cytometry
(black bars). Data shown are mean
(standard error) from six experiments.
*p,0.05 compared with control.
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ALI/ARDS, were included as an at risk-population. Non-
smoking, age-matched ventilated patients undergoing elective
surgery were recruited as controls.
Biological sample collection and processing
BAL using 150 ml cold saline was performed immediately after
recruitment in at-risk patients and ventilated controls and at
baseline and on day 4 in patients with ALI/ARDS. BAL fluid was
kept on ice until transferred to the laboratory for processing.
Blood was simultaneously collected in lithium heparin tubes
(Becton-Dickinson, Plymouth, UK) and placed immediately on
ice until processed.
The BAL fluid was filtered through coarse surgical gauze to
remove mucus and other debris. The fluid was then centrifuged
at 500 g for 5 min in a centrifuge prechilled to 4 C˚. The
supernatant was removed and immediately frozen to 280 C˚
and stored for subsequent analysis. The cell pellet was
resuspended in 10 ml phosphate-buffered saline supplemented
with 1% human serum albumin. Total cell count was
determined using a haemocytometer. Cell viability was mea-
sured by the ability of live cells to exclude Trypan Blue. Cell
purity was measured on a cytospin preparation stained with
DiffQuick (Baxter, Berkshire, UK) as described previously .23
Patient characterist ics
Patient demographic characteristics were recorded at baseline.
The acute physiology and chronic health evaluation II
(APACMEII) and simplified acute physiology score II
(SAPSII) scores, and predicted intensive care unit mortality
were recorded as global markers of disease severity.24 The
Murray Lung Injury Score and PaO2:FiO2 ratio were collected as
markers of the severity of lung injury.
Alveolar–capil lary permeabili ty
The single indicator transpulmonary thermodilution system
(PiCCO; Pulsion Medical Systems, Munich, Germany) was used
to calculate an in vivo alveolar–capillary permeability index.
The permeability index was derived from the ratio of
extravascular lung water to pulmonary blood volume.
Previous studies have shown that this index can separate
cardiogenic (low permeability) and inflammatory (high perme-
ability) causes of pulmonary oedema.25
Flow cytometry analysis
Flow cytometry was performed using the whole-blood techni-
que.26 Aliquots of 100 ml of whole blood or BAL cells (suspended
in 1% human serum albumin (Sigma Chemicals) at a final
concentration of 16106/ml) were fixed by adding 100 ml of 1%
paraformaldehyde for 15 min. Immunofluorescent staining was
performed by adding fluorescin isothiocyante isomer-conju-
gated monoclonal antibodies directed against the following:
CD11B (IgG1, Dako, Ely, UK); CD18 (IgG1, Dako); CD49 (IgG1,
Serotec, Oxford, UK), CD64 (IgG1, Serotec) and L-selectin,
IgG1, (Becton-Dickinson). Stimulated neutrophil L-selectin
expression was determined by incubating whole blood with
FMLP (1026 M) for 15 min before fixation. Controls were
included using isotype-matched, irrelevant antibodies to
human IgG1 (Dako). After incubation with the appropriate
monoclonal antibody for 30 min at room temperature (pro-
tected from light), 1.5 ml of FACS brand lysing solution
(Becton-Dickinson) was added to each tube for 5 min. The
cells were then washed twice with 1.5 ml of wash buffer
(500 ml phosphate-buffered saline, 0.1 g sodium azide (Sigma
Chemicals), 5 g bovine serum albumin (Sigma)). After the
second wash, the cell pellet was resuspended in 500 ml of 1%
paraformaldehyde. Samples were analysed on a Becton-
Dickinson 440 flow cytometer. The neutrophil cell populations
were identified and gated from the forward and side light
scatter. The median intensity of fluorescence for cells labelled
with specific antibody was determined relative to the median
intensity of fluorescence for cells labelled with the non-specific
isotype control antibody.
Tumor necrosis factor a, interleukin 8, MPO and
salbutamol assays
Tumor necrosis factor a (TNFa) and interleukin (IL)8 levels in
BAL fluid were measured using a commercially available ELISA
(R&D systems, Abingdon, UK). BAL MPO was measured using
the chromogenic substrate assay as described previously.23
Salbutamol levels were measured using a commercially avail-
able ELISA (Biox diagnostics, Jemelle, Belgium).
Statistical analysis
The study was powered to detect a 60% reduction in alveolar
neutrophil sequestration based on recent data showing that b2-
agonists reduce pulmonary neutrophil sequestration in human
volunteers exposed to LPS by 60%.18 We calculated that nine
patients would need to be recruited in each arm to detect this
difference with 80% power at a significance level of 0.05.
Differences between groups were examined by analysis of
variance or the Kruskal–Wallis test. Where significant differ-
ences were identified, Tukey’s test or the Mann–Whitney U test
was used to further examine the differences. Repeated
measures of neutrophil counts were non-parametric and
analysed by Friedman’s repeated measures test. Linear associa-
tions were tested using Pearsons correlation test. Data are
expressed as mean (standard deviation) unless otherwise
stated; p ,0.05 was considered significant.
RESULTS
In vitro studies
Neutrophil migration towards the chemotractant stimulus
FMLP was greater than that towards the RPMI control
(11.6 mm (1.2) versus 3.6 mm (0.2), p,0.001). Salbutamol at
Table 1 Baseline demographics for patients at risk from acute respiratory distress syndrome
and patients with established acute respiratory distress syndrome
ARDS
(n = 35)
At risk
(n = 19) p Value 95% CI
P:F ratio mm Hg (kPa) 106 (92) (33.5 (12.1)) 155 (92) (14.9 (5.8)) ,0.001 95–185 (12.5 to 24.4)
Lung injury score 2.9 (0.6) 1.2 (0.3) 0.001 1.3 to 1.9
SOFA score 13.4 (3.7) 6.7 (4.3) 0.001 4.1 to 9.2
APACHE II 23.4 (6.9) 21.7 (8.9) 0.312 22.1 to 6.5
SAPS II 52.0 (15.7) 54.8 (12.8) 0.550 212.0 to 6.4
Direct lung injury 13 (37%) 6 (32%) 0.771
Indirect lung injury 22 (63%) 13 (68%)
APACHE, acute physiology and chronic health evaluation; ARDS, acute respiratory distress syndrome; SAPS, simplified
acute physiology score; SOFA, sequential organ failure assessment.
38 Perkins, Nathani, McAuley, et al
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1024 and 1025 M significantly reduced neutrophil chemotaxis
(fig 1A). There was no effect on random neutrophil chemokin-
esis (fig 1B). The effect of salbutamol on neutrophil chemotaxis
was abolished by propranolol (fig 1C). Salbutamol 1024 to
1026 M had no effect on cellular viability (data not shown) or
neutrophil apoptosis (fig 1D).
Clinical studies
Patient baseline demographics
Forty patients with ALI/ARDS were initially recruited, of whom
35 had BAL performed at baseline and were included in this
study. Fourteen patients with risk factors for ARDS but who
had not developed ARDS at the time of BAL formed the at risk
group. Some of the data from the at risk group (BAL MPO levels
and neutrophil counts) have been published previously.23 Seven
ventilated controls were recruited. Table 1 shows the baseline
data on severity of illness and aetiology of lung injury for the
patients with ARDS and those at risk.
Neutrophilic inflammation is present in the alveolar
space in patients with ARDS
Evidence of increased accumulation of neutrophils and
neutrophilic inflammation was found in the BAL fluid of
patients with ARDS. Total neutrophil count, MPO, TNFa and
IL8 levels were raised in patients with ARDS compared with
patients at risk from ARDS and normal ventilated controls (fig 2
(A–D)). We found significant, albeit weak, linear associations
between the PiCCO alveolar–capillary permeability index and
MPO (r = 0.4, p = 0.038) and IL8 (r = 0.37, p = 0.033) levels.
Compared with normal controls, there was evidence of
increased adhesion molecule expression CD11B, CD18, CD49,
reduced L-selectin expression and increased neutrophil activa-
tion (CD64) on circulating and alveolar neutrophils (fig 3).
In vivo effects of salbutamol
From the initial group of patients randomised to salbutamol or
placebo, follow-up samples of blood and BAL fluid were
collected from 22 patients at day 4 (9 randomised to salbutamol
and 13 to placebo). Salbutamol was detected by ELISA in the
plasma of the treatment group at a concentration equivalent to
1026 M (range 250–495 ng/ml). The ELISA did not perform
reproducibly in the BAL matrix.
Circulating neutrophils
Treatment with intravenous salbutamol significantly increased
the number of circulating neutrophils (fig 4). There was a trend
towards reduced L-selectin expression on unstimulated neu-
trophils in the salbutamol group (placebo 55 (19) v salbutamol
39 (30), p = 0.18). When neutrophils were stimulated ex vivo
with FMLP, neutrophils from salbutamol-treated patients had
significantly lower L-selectin expression (placebo 43 (15) v
salbutamol 22 (21), 95% confidence interval (CI) 1.2 to 39,
p = 0.038; fig 5). We found no effect on integrin adhesion
molecule expression measured at day 4 (CD11B, CD18 or CD49)
or expression of the neutrophil activation marker CD64 (fig 3A).
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Figure 2 (A) Bronchoalveolar lavage
neutrophil count, (B) myeloperoxidase, (C)
tumour necrosis factor a (TNFa) and (D)
interleukin (IL)8 in normals, patients at risk
from acute lung injury (ALI)/acute
respiratory distress syndrome (ARDS) and
patients with ALI/ARDS at baseline and after
4 days of treatment with intravenous
salbutamol (salb).
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Pulmonary neutrophils and alveolar inflammation
In contrast to the plasma compartment, there was no difference
in BAL fluid neutrophil count between groups at day 4 (placebo
3.5 (0.6) v salbutamol group 1.6 (1.7), p = 0.4; fig 2A).
Adhesion molecule expression was also similar in the two
groups and there was no difference in the expression of the
neutrophil activation marker CD64 (fig 3B). We found no
difference in L-selectin expression (unstimulated cells: placebo
3 (4) v salbutamol 4 (6), p = 0.753; FMLP stimulated cells:
placebo 1.7 (2) v salbutamol 1.8 (3), p = 0.9). We also found no
differences in myeloperoxidase (fig 2B), TNFa (fig 2C) or IL8
(fig 2D).
DISCUSSION
In a double-blind randomised placebo-controlled trial, we
showed that sustained treatment with intravenous salbutamol
considerably reduced extravascular lung water in humans with
ALI/ARDS.19 In contrast with our initial hypothesis and
supporting data from animal studies,27 the response was not
evident until 48 h after the initiation of treatment. Our study
sought to identify whether salbutamol was having an effect on
pulmonary neutrophil accumulation and alveolar inflamma-
tion. Our study confirms previous observations that there is
increased neutrophil accumulation and inflammation in the
alveolar space in people with ALI/ARDS. The novel finding of a
positive association between the intensity of neutrophilic
infiltration and an in vivo measurement of alveolar–capillary
permeability adds additional support to the hypothesis that the
neutrophil is a key inflammatory mediator in ARDS. Contrary
to in vitro, animal and healthy volunteer studies, we found no
evidence that intravenous salbutamol modulated alveolar
neutrophil accumulation, activation or markers of alveolar
inflammation in humans with ALI/ARDS.
Studies investigating the in vitro effects of b-agonists on
neutrophil chemotaxis have produced conflicting results,
probably due to differences in the specific b2-agonist tested,
the dose used and the experimental conditions. Some studies
showed a reduction in neutrophil chemotaxis,28 29 whereas
others reported a biphasic response with increased neutrophil
chemotaxis at low concentrations of b2-agonist and a reduction
in chemotaxis at higher concentrations.30 Our study reports for
the first time that the physiological concentration of salbutamol
achieved in the plasma after an intravenous infusion of
salbutamol (15 mg/kg/h) in patients with ALI/ARDS is
1026 M. At this concentration, no effect on neutrophil
chemotaxis was observed. Supraphysiological concentrations
(1024 and 1025 M), however, reduced neutrophil chemotaxis
through activation of the b-receptor. Moreover, physiologically
relevant concentrations of salbutamol had no effect on
neutrophil viability or the rate of spontaneous apoptosis
measured by morphology and annexin V/propidium iodine
staining.
The mechanisms regulating pulmonary neutrophil seques-
tration have been well characterised. Pulmonary neutrophil
sequestration occurs within minutes of exposure to an
inflammatory insult.31 32 The insult causes an increase in
neutrophil stiffness and reduction in deformability,33 leading
to sequestration into the pulmonary capillaries, followed by
emigration into the alveolar space. The process of neutrophil
emigration occurs by at least two differentially regulated
pathways: CD11/18 adhesion molecule interactions determine
the response to Gram-negative organisms, IL1a and phorbol 12-
myristate 13-acetate, whereas Gram-positive organisms, hyper-
oxia and the complement anaphylatoxins (C5a) seem to induce
neutrophil emigration through a CD11/18-independent path-
way.34
Animal models of direct13 and indirect14 lung injury have
shown that pretreatment with intravenous b2-agonists reduces
pulmonary neutrophil sequestration by 30%. In normal human
volunteers, in a placebo-controlled trial, treatment with 300 mg
inhaled salbutamol prevented platelet-activating factor-
induced pulmonary sequestration of radiolabelled neutrophils.35
Pretreatment with salmeterol similarly inhibited LPS-induced
neutrophil influx, neutrophil degranulation (myeloperoxidase)
and TNFa release in human volunteers.18 Reduced neutrophil–
endothelial adhesion, through the down regulation of neutro-
phil integrin adhesion molecule expression (CD11B/18) seen
with b2-agonists may partly explain this finding.
36
In our study, intravenous salbutamol considerably increased
circulating neutrophil count but had no apparent effect on
alveolar neutrophil counts. The increase in circulating neutro-
phils induced by b-agonists is thought to be due to detachment
of cells from the marginating neutrophil pools rather than
mobilisation of neutrophils from the bone marrow.37 Neutrophil
L-selectin expression may be important in this effect because of
a dominant role in the initial slowing, margination and rolling
behaviour of neutrophils over the endothelim at the post-
capillary venule in the systemic circulation.38 The shedding of L-
selectin from the neutrophil surface allows neutrophils to break
free from the vascular endothelium and return to the
circulation. The mobilisation of neutrophils was not, however,
associated with any difference in the degree of organ dysfunc-
tion between the two groups.19
In contrast to the systemic circulation, where neutrophil
sequestration usually occurs at the post-capillary venule,
neutrophil migration in the lung occurs at the pulmonary
capillaries, without dependence on L-selectin-mediated roll-
ing.39 In our study, we found a trend towards reduced L-selectin
expression on circulating neutrophils in patients treated with
salbutamol. When the neutrophils were maximally stimulated
with FMLP, neutrophils primed by treatment with salbutamol
showed a notably greater reduction in L-selectin expression
than those treated with placebo. This finding is consistent with
the observation that isoprotenerol reduces neutrophil L-selectin
expression in human volunteers.40 Enhanced L-selectin shed-
ding would increase neutrophil mobilisation from the systemic
circulation and may explain the finding of increased circulating
neutrophils. By contrast, the absence of a measurable effect of
salbutamol on integrin adhesion molecule expression relevant
to pulmonary neutrophil emigration may explain the observed
lack of effect on pulmonary neutrophil sequestration.
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Figure 3 Treatment with intravenous salbutamol significantly increased
circulating neutrophil count (p = 0.004). Data are shown as mean (SE) for
salbutamol (squares/grey dotted line) and placebo (circles/solid line).
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There are several other potential explanations for the absence
of a measurable effect of salbutamol in vivo on alveolar
neutrophil accumulation and inflammation. Firstly, pulmonary
neutrophil emigration occurs within minutes of exposure to the
toxic insult.31 32 In the previous studies that reported a
reduction in pulmonary neutrophil sequestration with b-
agonists, the drug was administered before the inflammatory
insult.13 14 18 35 In our study, salbutamol was given many hours
after the initial insult, potentially therefore too late to have an
effect on pulmonary neutrophil recruitment. Although the
study was relatively small, it is similar in size to previous
studies,13 14 18 35 and was powered to detect a treatment effect of
a magnitude similar to that observed in previous studies. We
cannot, however, exclude that a smaller treatment effect would
not have been observed with greater numbers, although the
clinical relevance of smaller changes is unclear. Further,
multiple signalling pathways enhance neutrophil emigration
in patients with ARDS, which may differ depending on the
aetiology of ARDS. Our study was not powered to investigate
the effects of salbutamol on neutrophil inflammation because
of different aetiologies, and so cannot exclude an effect in some
causes of ARDS. Finally, alveolar neutrophil recruitment was
only studied at baseline and 4 days after the initiation of
treatment (up to 6 days after the onset of ARDS). In both
treatment and placebo groups, neutrophil counts were
markedly lower on day 4 than at the point of initial
recruitment. Therefore, we cannot exclude that salbutamol
may have had an effect earlier in the course of the disease,
which by virtue of the timing of alveolar sampling, may have
been missed.
CONCLUSION
At the onset of ALI/ARDS, there is increased pulmonary
neutrophil recruitment and activation in addition to positive
correlations between IL8, myeloperoxidase and alveolar–capil-
lary permeability, suggesting an association between neutrophil
activation and the development of lung injury. In vitro,
physiological concentrations of salbutamol failed to show an
effect on neutrophil chemotaxis, viability or apoptosis. Treating
patients with ALI/ARDS with intravenous salbutamol increased
the number of circulating neutrophils, but had no effect on
alveolar neutrophil numbers or on neutrophil activation or
alveolar inflammation. The beneficial effects of salbutamol in
reducing extravascular lung water seem to be unrelated to the
modulation of neutrophilic inflammatory pathways.
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